Dasatinib藥物市場：按類型、適應症、分銷管道和地區分類

Dasatinib Drugs Market, By Type, By Indication, By Distribution Channel, By Geography

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

Dasatinib藥物市場預計在 2026 年達到 17.482 億美元，預計到 2033 年將達到 26.635 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 6.2%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	17.482億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	6.20%	2033年市場規模預測：	26.635億美元

Dasatinib是一種極具前景的蛋白酪氨酸激酶抑制劑，它徹底改變了某些類型癌症的治療。Dasatinib最初是作為慢性骨髓性白血病(CML) 和費城染色體陽性急性淋巴細胞白血病 (Ph+ALL) 的標靶標靶治療而開發的，它特異性靶向 BCR-ABL 蛋白，抑制其活性，從而抑制癌細胞增殖。其顯著的療效顯著改善了這些惡性腫瘤患者的預後和存活率。此外，Dasatinib還能抑制其他蛋白酪氨酸激酶，包括 SRC 家族激酶，從而拓展了其在更廣泛腫瘤中的應用範圍。儘管DasatinibDasatinib一種很有前景的治療選擇，但它並非沒有副作用，需要密切監測和管理。目前正在進行的研究和臨床試驗正在探索Dasatinib聯合治療的潛力，為癌症治療策略的進一步發展鋪平道路。

市場動態

癌症發生率的上升、良好的臨床療效以及核准適應症的擴大，預計將推動全球Dasatinib市場在預測期內成長。此外，標靶治療的研發預計也將促進全球Dasatinib市場在預測期內的成長。進入新興市場、聯合治療、兒童適應症以及學名藥的研發，預計將在預測期內為全球Dasatinib市場創造成長機會。

然而，高昂的治療費用、嚴格的監管要求、潛在的副作用以及抗藥性的產生預計將在預測期內阻礙Dasatinib藥物市場的成長。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球Dasatinib市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份《全球Dasatinib藥物市場》報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球Dasatinib藥物市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 南非
- 中非

第8章競爭情勢

Bristol-Myers Squibb
MSN Labs
Hetero Labs
Alembic Pharma
JINLAN Pharm-Drugs Technology Co., Ltd.
Reddy's
Zhejiang Hisun Pharma

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI5963

Dasatinib Drugs Market is estimated to be valued at USD 1,748.2 Mn in 2026 and is expected to reach USD 2,663.5 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,748.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.20%	2033 Value Projection:	USD 2,663.5 Mn

Dasatinib is a potential tyrosine kinase inhibitor that has revolutionized the treatment landscape for certain types of cancer. Initially developed as a targeted therapy for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), dasatinib specifically targets and inhibits the BCR-ABL protein, suppressing the growth and proliferation of cancer cells. With remarkable efficacy, dasatinib has significantly improved outcomes and increased survival rates in patients with these malignancies. Moreover, dasatinib exhibits inhibitory effects on other tyrosine kinases, including SRC family kinases, broadening its potential application to various tumors. While dasatinib offers a promising therapeutic option, it is not without side effects, necessitating careful monitoring and management. Ongoing research and clinical trials are exploring the potential of dasatinib in combination therapies, paving the way for further advancements in cancer treatment strategies.

Market Dynamics:

The increasing prevalence of cancer, favorable clinical outcomes, and expansion of approved indications are anticipated to drive the growth of the global dasatinib drugs market over the forecast period. Moreover, the development of targeted therapies is also expected to boost the growth of the global dasatinib drugs market over the forecast period. Expansion into emerging markets, combination therapies, pediatric indications, and the development of generic versions are expected to create growth opportunities for the global dasatinib drugs market growth during the forecast period.

However, the high cost of treatment, stringent regulatory requirements, potential adverse effects, the development of resistance are expected to hamper the growth of the dasatinib drugs market over the forecast period.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dasatinib drugs market based on the following parameters - company highlights, product portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, MSN Labs, Lupin, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Hetero Labs, MANUS AKTTEVA BIOPHARMA LLP, Alembic Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., and Zhejiang Hisun Pharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dasatinib drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dasatinib drugs market

Detailed Segmentation:

Dasatinib Drugs Market, By Type (Revenue, USD Mn, 2021 - 2033)
20 mg
50 mg
70 mg
Dasatinib Drugs Market, By Indication (Revenue, USD Mn, 2021 - 2033)
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Others
Dasatinib Drugs Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
Bristol-Myers Squibb
MSN Labs
Lupin
Dr. Reddy's Laboratories
Hetero Labs
MANUS AKTTEVA BIOPHARMA LLP
Alembic Pharma
JINLAN Pharm-Drugs Technology Co., Ltd.
Reddy's Laboratories
Zhejiang Hisun Pharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By Indication
- Market Snippet, By Distribution channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
  - Increasing prevalence of cancer
- Restraints
  - Increasing product recall
- Opportunities
  - Expansion into emerging markets
  - Combination therapies
  - Pediatric indications
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Dasatinib Drugs Market, By Type, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
20 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
50 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
70 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

5. Dasatinib Drugs Market, By Indication, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Chronic Myeloid Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Acute Lymphoblastic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

6. Dasatinib Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

7. Dasatinib Drugs Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022 -2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - U.S.
  - Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Mn)
  - North Africa
  - South Africa
  - Central Africa

8. Competitive Landscape

Bristol-Myers Squibb
- Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- MSN Labs
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Hetero Labs
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Alembic Pharma,
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- JINLAN Pharm-Drugs Technology Co., Ltd.,
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Reddy's,
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Zhejiang Hisun Pharma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Analyst Views